SEC Form 10-Q filed by Maze Therapeutics Inc.
$MAZE
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/4/2025 | $55.00 | Overweight | Wells Fargo |
| 11/14/2025 | Outperform | Raymond James | |
| 9/2/2025 | $30.00 | Buy | BTIG Research |
| 7/23/2025 | $34.00 | Buy | H.C. Wainwright |
| 7/8/2025 | $17.00 | Outperform | Wedbush |
S-8 - Maze Therapeutics, Inc. (0001842295) (Filer)
S-3ASR - Maze Therapeutics, Inc. (0001842295) (Filer)
8-K - Maze Therapeutics, Inc. (0001842295) (Filer)
4 - Maze Therapeutics, Inc. (0001842295) (Issuer)
4 - Maze Therapeutics, Inc. (0001842295) (Issuer)
4 - Maze Therapeutics, Inc. (0001842295) (Issuer)
SOUTH SAN FRANCISCO, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (NASDAQ:MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced that Jason Coloma, Ph.D., chief executive officer of Maze Therapeutics, will present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11, 2026 at 3:00 p.m. ET. A live webcast of the event will be available in the Investors section of the Maze Therapeutics website at www.mazetx.com and archived for 60 days following the presentation. About Maze Therapeutics Maze Therapeutics is a clinical-stage biopharmaceu
SOUTH SAN FRANCISCO, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (NASDAQ:MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced that Jason Coloma, Ph.D., chief executive officer of Maze Therapeutics, will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 8:15 a.m. PT. A live webcast of the event will be available in the Investors section of the Maze Therapeutics website at www.mazetx.com and archived for 30 days following the presentation. About Maze Therapeutics Maze Therapeutics is a clinical-stage biopharmaceutical c
First-in-human data from Phase 1 trial of MZE782 support best- and first-in-class potential; two Phase 2 proof-of-concept trials in phenylketonuria (PKU) and chronic kidney disease (CKD) expected to initiate in 2026 Enrollment ongoing in Phase 2 HORIZON trial of MZE829 in broad APOL1-mediated kidney disease (AMKD); topline data for initial patients expected by the end of Q1 2026 Strong balance sheet with $383.9 million in cash, cash equivalents and marketable securities following oversubscribed private placement; cash runway into 2028 SOUTH SAN FRANCISCO, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (NASDAQ:MAZE), a clinical-stage biopharmaceutical company developin
Wells Fargo initiated coverage of Maze Therapeutics with a rating of Overweight and set a new price target of $55.00
Raymond James initiated coverage of Maze Therapeutics with a rating of Outperform
BTIG Research initiated coverage of Maze Therapeutics with a rating of Buy and set a new price target of $30.00
Phase 1 data in healthy volunteers exceed expectations and support best-in-class potential, enabling Phase 2 advancement for both intended indications of PKU and CKD Dose-dependent urinary amino acid excretion demonstrated across all SAD and MAD cohorts, including up to a 42-fold increase in urinary phenylalanine (Phe) excretion, a well-validated biomarker for PKU and predictive for CKD Dose-dependent initial eGFR dip similar to SGLT2 inhibitors observed, supporting a potential kidney protective effect in CKD Well tolerated across all doses with an excellent safety profile and no serious adverse events observed Phase 2 trials in both PKU and CKD expected to initiate in 2026 Maze to hos
First-in-human data from Phase 1 trial of MZE782 support best- and first-in-class potential; two Phase 2 proof-of-concept trials in phenylketonuria (PKU) and chronic kidney disease (CKD) expected to initiate in 2026 Enrollment ongoing in Phase 2 HORIZON trial of MZE829 in broad APOL1-mediated kidney disease (AMKD); topline data for initial patients expected by the end of Q1 2026 Strong balance sheet with $383.9 million in cash, cash equivalents and marketable securities following oversubscribed private placement; cash runway into 2028 SOUTH SAN FRANCISCO, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (NASDAQ:MAZE), a clinical-stage biopharmaceutical company developin
SOUTH SAN FRANCISCO, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (NASDAQ:MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced the appointment of Hervé Hoppenot as Chairman of its Board of Directors, succeeding Charles Homcy, M.D., who will continue to serve on the Board. "I am honored to assume the role of Chairman of the Board at this pivotal moment for Maze Therapeutics," said Mr. Hoppenot. "With encouraging first-in-human data for MZE782, an oversubscribed $150 million private placement, and important clinical milestones ahead, including the advancement of M